In reality, PPARĪ³ agonist markedly sensitized bladder cancer cell lines, particularly those that were resistant to EGFR inhibition, in a schedule-specific manner, suggesting it can be an excellent alternative when cells are resistant to the aforementioned monotherapies.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}